PVCT Provectus Biopharmaceuticals - Correlation between Tumor Mutational Burden and Objective Response Rate with Anti–PD-1 or Anti-PD–L - PVCT Provectus Biopharmaceuticals - InvestorVillage
PVCT Provectus Biopharmaceuticals

  • Investor Village needs your help. We are working hard to improve your user experience
    by upgrading the site so it works better on the latest mobile devices, browsers, O/S, etc. Because costs exceed our normal operating budget, we are asking everyone, including "lurkers," to support our efforts.

    Click this PayPal link to make a one-time contribution in whatever amount you think is fair.

    Or click here to support us with a monthly contribution, starting as low as $2.50 per month.

    Payments can be made directly via PayPal or Credit Card with no need to create an Investor Village account. Cancel any time.

This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: PVCT Provectus Biopharmaceuticals   /  Message Board  /  Read Message

 
 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  4317 of 4716  at  7/11/2019 10:04:05 AM  by

Hombre77


 In response to msg 4315 by  leave_the_gun
view thread

Re: Correlation between Tumor Mutational Burden and Objective Response Rate with Anti–PD-1 or Anti-PD–L1 Therapy in 27 Tumor Types

If a BP was to make a takeout offer now, what would it be?  Let's say somebody offered a 400% premium, which would be unusually high relative to historical transactions.  That would give us what - $.35/share?  Although that sounds pretty good relative to $.07, I don't think it's what most shareholders (other than ratchet warrant owners) are looking for. 
 
A better path for shareholders would be to obtain some type of FDA approval, which would bring the Holy Grail of serious third party validation and should push the share price up to at least $.50.  From there, any takeover offer would need to be at $1.00+.  Not to mention that with an approval in hand, there's a higher probability that competing offers would materialize from other companies that don't want to be left in the dust in terms of safe & efficacious complementary drugs to partner with their checkpoint inhibitors in the vast cold tumor space.
 
I think that's why management is aggressively pursuing trials for serious orphan diseases that have high unmet needs -  e.g. metastatic uveal melanoma & NETs.  


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 3     Views: 214
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
4318 Re: Correlation between Tumor Mutational Burden and Objective Response Rate with Anti–PD-1 or Anti-PD–L1 Therapy in 27 Tumor Types PVCTismyBMW 8 7/11/2019 10:45:45 AM
4323 Re: Correlation between Tumor Mutational Burden and Objective Response Rate with Anti–PD-1 or Anti-PD–L1 Therapy in 27 Tumor Types Stringfellow7777 0 7/11/2019 12:40:39 PM


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...